Enhancement of latent inhibition in the rat by the atypical antipsychotic agent remoxipride. (Q52195493)

26 April 2018

title

Enhancement of latent inhibition in the rat by the atypical antipsychotic agent remoxipride. (English)

1 reference

26 April 2018

author name string

Trimble KM

series ordinal

1

1 reference

26 April 2018

Bell R

series ordinal

2

1 reference

26 April 2018

King DJ

series ordinal

3

1 reference

26 April 2018

language of work or name

English

0 references

publication date

1 April 1997

1 reference

26 April 2018

Pharmacology, Biochemistry and Behavior

published in

1 reference

26 April 2018

volume

56

1 reference

26 April 2018

issue

4

1 reference

26 April 2018

page(s)

809-816

1 reference

26 April 2018

Stimulation of brain dopamine autoreceptors by remoxipride administration in reserpine-treated male rats.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Differential performance of acute and chronic schizophrenics in a latent inhibition task.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride — an123I-IBZM single photon emission tomography (SPET) study

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Haloperidol enhancement of latent inhibition: Relation to therapeutic action?

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Amphetamine-produced attenuation of latent inhibition is modulated by stimulus preexposure duration: implications for schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioral model of clinical drug action.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Distribution of remoxipride to the human brain and central D2-dopamine receptor binding examined in vivo by PET

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Latent inhibition is unaffected by direct dopamine agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Long-term attentional deficit in nonhandled males: possible involvement of the dopaminergic system

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

The atypical antipsychotic, remoxipride, blocks phencyclidine-induced disruption of prepulse inhibition in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: effects of antipsychotics and other agents in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Effects of the neuroleptic alpha-flupenthixol on latent inhibition in aversively- and appetitively-motivated paradigms: evidence for dopamine-reinforcer interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Differential effects of intra-accumbens and systemic amphetamine on latent inhibition using an on-baseline, within-subject conditioned suppression paradigm.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Biochemical pharmacology of the atypical neuroleptic remoxipride

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Clinical profile of remoxipride--a combined analysis of a comparative double-blind multicentre trial programme

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

A theory of attention: Variations in the associability of stimuli with reinforcement

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Comparison of the effects of haloperidol, remoxipride and raclopride on "pre"- and postsynaptic dopamine receptors in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Effects of the dopamine D2 selective receptor antagonist remoxipride on dopamine turnover in the rat brain after acute and repeated administration

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

MDL 73,147EF, a 5-HT3 antagonist, facilitates latent inhibition in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Concentrations of remoxipride and its phenolic metabolites in rat brain and plasma. Relationship to extrapyramidal side effects and atypical antipsychotic profile

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Is the sigma opiate receptor a proadifen-sensitive subform of cytochrome P-450?

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

CNS dopamine autoreceptors: distribution, pharmacology, and function

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Neural substrates of latent inhibition: the switching model

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Facilitation of latent inhibition by haloperidol in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

The latent inhibition model of schizophrenic attention disorder and of antipsychotic drug action: comment on Dunn, Atwater and Kilts (Psychopharmacology, 1993, 112:315-323)

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

The effects of the new antipsychotic, sertindole, on latent inhibition in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Disruption of latent inhibition by acute administration of low doses of amphetamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

10.1016/S0091-3057(96)00483-2

Identifiers

DOI

1 reference

26 April 2018

PubMed ID

9130309

1 reference

26 April 2018